April 12th 2024
LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced Cancers
November 16th 2021Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21st 2021A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.